Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the safety and efficacy, including the incidence of thromboembolism, in renal anemia patients treated with roxadustat (EVRENZO® Tablets) in actual clinical settings.
This is a post-marketing long-term specified drug use-result survey study required for products in Japan. In the survey, patient registration and data collection will be conducted using post-marketing survey data collection system, PostMaNet via the Internet.
Patients who are eligible for the survey will be registered within 14 days after the start of treatment with roxadustat (including the start day of treatment). For all registered patients (including discontinuations/dropouts), the investigator will enter the necessary information in the case report form (CRF) and send it immediately after the end of the specified observation period for each patient.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Roxadustat | Participants will receive oral dose of roxadustat. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Roxadustat | Drug | Oral |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants with Adverse Drug Reactions (ADR) | An AE is defined as any unwanted medical occurrence after drug administration and which does not necessarily have a causal relationship with the treatment. ADR is AEs whose relationship to the study drugs could not be ruled out is considered adverse drug reaction. AEs that fall under either "Probable" or "Possible" or "Unassessable" should be defined as "AEs whose relationship to the study drugs could not be ruled out. | Up to Week 104 |
| Proportion of participants with serious ADR | ADR is considered "serious" if, in the view of the investigator, the event: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires hospitalization or prolongation to hospitalization, or other medically important event. | Up to Week 104 |
| Proportion of participants with thromboembolism | Number of participants with thromboembolism compared to number of participants evaluated. | Up to Week 104 |
| Proportion of participants with hypertension | Number of participants with hypertension compared to number of participants evaluated. | Up to Week 104 |
| Proportion of participants with hepatic function disorder | Number of participants with hepatic function disorder compared to number of participants evaluated. | Up to Week 104 |
| Proportion of participants with malignant tumors |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Renal anemia patients on dialysis and non-dialysis who are naïve to roxadustat
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Astellas Pharma Inc. | Astellas Pharma Inc | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site JP00023 | Aichi | Japan | ||||
| Site JP00005 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39899733 | Derived | Tsuruya K, Sugamori H, Tanaka Y, Wakasugi N, Ito Y. Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan. Expert Opin Pharmacother. 2025 Mar;26(4):503-517. doi: 10.1080/14656566.2025.2462181. Epub 2025 Feb 7. |
Not provided
Not provided
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Number of participants with malignant tumors compared to number of participants evaluated.
| Up to Week 104 |
| Proportion of participants with retinal hemorrhage | Number of participants with retinal hemorrhage compared to number of participants evaluated. | Up to Week 104 |
| Proportion of Participants With Seizures | Number of participants with seizures will be reported. | Up to week 104 |
| Proportion of Participants With Serious Infection | Number of participants with serious infection will be reported. | Up to week 104 |
| Proportion of Participants With Central Hypothyroidsm | Number of participants with central hypothyroidsm compared to number of participants evaluated. | Up to Week 104 |
| Proportion of participants with myopathy events | Number of participants with myopathy events related to the concomitant use of hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors compared to number of participants evaluated. | Up to Week 104 |
| Proportion of Participants With Renal Function Disorder | Number of participants with renal function disorder reported as adverse drug reaction in participants with autosomal dominant polycystic kidney disease (ADPKD) will be reported. | Up to week 104 |
| Proportion of participants with ADR within 4 weeks after switching to roxadustat | Number of participants with ADR within 4 weeks after switching from erythropoiesis stimulating agent (ESA) to roxadustat compared to number of participants evaluated. | Up to Week 4 |
| Proportion of participants with ADR with high doses of roxadustat | Number of participants with ADR with high doses of roxadustat compared to number of participants evaluated. | Up to Week 104 |
| Change from baseline in Hemoglobin (Hb) levels | Hb will be recorded from blood samples collected. | Up to Week 104 |
| Mean value of Hb levels over time | Hb will be measured throughout the period. | Up to Week 104 |
| Achievement rate for target Hb level | Percent of participants who achieved target Hb level (10.0 to 12.0 g/dL). | Up to Week 104 |
| Mean Hb levels at 4 weeks after switching to roxadustat | Hb levels at 4 weeks after switching from ESA to roxadustat. | At Week 4 |
| Akita |
| Japan |
| Site JP00002 | Aomori | Japan |
| Site JP00012 | Chiba | Japan |
| Site JP00038 | Ehime | Japan |
| Site JP00018 | Fukui | Japan |
| Site JP00040 | Fukuoka | Japan |
| Site JP00007 | Fukushima | Japan |
| Site JP00021 | Gifu | Japan |
| Site JP00010 | Gunma | Japan |
| Site JP00034 | Hiroshima | Japan |
| Site JP00001 | Hokkaido | Japan |
| Site JP00028 | Hyōgo | Japan |
| Site JP00008 | Ibaraki | Japan |
| Site JP00017 | Ishikawa | Japan |
| Site JP00037 | Kagawa | Japan |
| Site JP00046 | Kagoshima | Japan |
| Site JP00014 | Kanagawa | Japan |
| Site JP00039 | Kochi | Japan |
| Site JP00043 | Kumamoto | Japan |
| Site JP00026 | Kyoto | Japan |
| Site JP00024 | Mie | Japan |
| Site JP00004 | Miyagi | Japan |
| Site JP00045 | Miyazaki | Japan |
| Site JP00020 | Nagano | Japan |
| Site JP00042 | Nagasaki | Japan |
| Site JP00029 | Nara | Japan |
| Site JP00015 | Niigata | Japan |
| Site JP00003 | Numakunai | Japan |
| Site JP00033 | Okayama | Japan |
| Site JP00047 | Okinawa | Japan |
| Site JP00027 | Osaka | Japan |
| Site JP00044 | Ōita | Japan |
| Site JP00041 | Saga | Japan |
| Site JP00011 | Saitama | Japan |
| Site JP00025 | Shiga | Japan |
| Site JP00032 | Shimane | Japan |
| Site JP00022 | Shizuoka | Japan |
| Site JP00009 | Tochigi | Japan |
| Site JP00036 | Tokushima | Japan |
| Site JP00013 | Tokyo | Japan |
| Site JP00031 | Tottori | Japan |
| Site JP00016 | Toyama | Japan |
| Site JP00030 | Wakayama | Japan |
| Site JP00006 | Yamagata | Japan |
| Site JP00035 | Yamaguchi | Japan |
| Site JP00019 | Yamanashi | Japan |
| ID | Term |
|---|---|
| C584543 | roxadustat |
Not provided
Not provided
Not provided